VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q42627694 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000159.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q42627694‏
024 ‎‡a 0000-0001-5470-3754‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q42627694‏
100 0 ‎‡a Jaime Caro‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Jaime Caro‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Jaime Caro‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A case-control study of risk factors for large bowel carcinoma.‏
670 ‎‡a Author's A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.‏
670 ‎‡a Author's Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.‏
670 ‎‡a Author's Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III guidelines.‏
670 ‎‡a Author's Alzheimer's disease and other dementia in nursing homes: levels of management and cost‏
670 ‎‡a Author's An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes‏
670 ‎‡a Author's An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 24).‏
670 ‎‡a Author's An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation‏
670 ‎‡a Author's An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.‏
670 ‎‡a Author's An interview with J. Jaime Caro.‏
670 ‎‡a Author's Are hypoglycaemia and other adverse effects similar among sulphonylureas?‏
670 ‎‡a Author's Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials‏
670 ‎‡a Author's Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.‏
670 ‎‡a Author's Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research‏
670 ‎‡a Author's Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries‏
670 ‎‡a Author's Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature‏
670 ‎‡a Author's Assessment of compliance with osteoporosis treatment and its consequences in a managed care population‏
670 ‎‡a Author's Assessment of Health Economics in Alzheimer's Disease‏
670 ‎‡a Author's Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care.‏
670 ‎‡a Author's Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden‏
670 ‎‡a Author's Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.‏
670 ‎‡a Author's Assessment of the association between blood pressure control and health care resource use‏
670 ‎‡a Author's Atrial fibrillation and anticoagulation: from randomised trials to practice‏
670 ‎‡a Author's Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment‏
670 ‎‡a Author's Bileaflet valve replacement: complications and costs‏
670 ‎‡a Author's Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials.‏
670 ‎‡a Author's Can cost utility evaluations inform decision making about interventions for low back pain?‏
670 ‎‡a Author's Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder‏
670 ‎‡a Author's Care needs and economic consequences after acute ischemic stroke: the Erlangen Stroke Project‏
670 ‎‡a Author's Case-control studies in pharmacoeconomic research: an overview.‏
670 ‎‡a Author's Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase‏
670 ‎‡a Author's Clinical and economic burden of infused iron chelation therapy in the United States‏
670 ‎‡a Author's Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers‏
670 ‎‡a Author's Compliance and hypertension‏
670 ‎‡a Author's Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with Schizophrenia in Quebec and Saskatchewan: A retrospective database study‏
670 ‎‡a Author's Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone‏
670 ‎‡a Author's [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain]‏
670 ‎‡a Author's Cost-Effectiveness of Cardiac Resynchronization Therapy‏
670 ‎‡a Author's Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.‏
670 ‎‡a Author's Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure‏
670 ‎‡a Author's Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.‏
670 ‎‡a Author's Cost-effectiveness of laparoscopic and mini-cholecystectomy in a prospective randomized trial.‏
670 ‎‡a Author's Cost of managing an episode of relapse in multiple sclerosis in the United States‏
670 ‎‡a Author's Cost of managing complications resulting from type 2 diabetes mellitus in Canada‏
670 ‎‡a Author's Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPPHIRE trial‏
670 ‎‡a Author's Costs and effectiveness of extracorporeal gallbladder stone shock wave lithotripsy versus laparoscopic cholecystectomy. A randomized clinical trial. McGill Gallstone Treatment Group‏
670 ‎‡a Author's Costs and Medical Care Consequences Associated with the Diagnosis of Peripheral Arterial Disease‏
670 ‎‡a Author's Could chest X-ray screening for lung cancer be cost-effective?‏
670 ‎‡a Author's Decision-analytic models: current methodological challenges.‏
670 ‎‡a Author's Describing cognitive decline of patients at the mild or moderate stages of Alzheimer's disease using the Standardized MMSE.‏
670 ‎‡a Author's Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management‏
670 ‎‡a Author's Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).‏
670 ‎‡a Author's Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications‏
670 ‎‡a Author's Direct medical costs of complications resulting from type 2 diabetes in the U.S.‏
670 ‎‡a Author's Discrete event simulation: the preferred technique for health economic evaluations?‏
670 ‎‡a Author's Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics‏
670 ‎‡a Author's Does electronic implementation of questionnaires used in asthma alter responses compared to paper implementation?‏
670 ‎‡a Author's Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands‏
670 ‎‡a Author's Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy‏
670 ‎‡a Author's Economic and health consequences of managing bradycardia with dual-chamber compared to single-chamber ventricular pacemakers in Italy.‏
670 ‎‡a Author's Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes‏
670 ‎‡a Author's Economic assessments of low molecular weight heparin in venous thromboembolism‏
670 ‎‡a Author's Economic burden of pertussis and the impact of immunization‏
670 ‎‡a Author's Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial‏
670 ‎‡a Author's Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation‏
670 ‎‡a Author's Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States‏
670 ‎‡a Author's Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial‏
670 ‎‡a Author's Economic implications of growth hormone use in patients with short bowel syndrome‏
670 ‎‡a Author's Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis‏
670 ‎‡a Author's Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.‏
670 ‎‡a Author's Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review‏
670 ‎‡a Author's Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis‏
670 ‎‡a Author's Ethene/ethane and propene/propane separation via the olefin and paraffin selective metal-organic framework adsorbents CPO-27 and ZIF-8.‏
670 ‎‡a Author's Evaluating the true cost of hypertension management: evidence from actual practice.‏
670 ‎‡a Author's Existing treatment strategies: does noncompliance make a difference?‏
670 ‎‡a Author's Foundations of medical diagnosis: what actually are the parameters involved in Bayes' theorem?‏
670 ‎‡a Author's Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events‏
670 ‎‡a Author's Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials‏
670 ‎‡a Author's Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France‏
670 ‎‡a Author's Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis‏
670 ‎‡a Author's Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus‏
670 ‎‡a Author's Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K‏
670 ‎‡a Author's HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis‏
670 ‎‡a Author's Hospitalization for pertussis: profiles and case costs by age.‏
670 ‎‡a Author's How cost-effective are drugs and devices used in cardiology?‏
670 ‎‡a Author's How relevant is cost-effectiveness anyway?‏
670 ‎‡a Author's Ignoring Study Design Heterogeneity in Meta-analyses‏
670 ‎‡a Author's Impact of Physical Functioning of Health Status on Hospitalizations, Physician Visits, and Costs in Diabetic Patients‏
670 ‎‡a Author's Impact of thalassemia major on patients and their families‏
670 ‎‡a Author's Improving Transparency in Decision Models: Current Issues and Potential Solutions‏
670 ‎‡a Author's Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha‏
670 ‎‡a Author's International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.‏
670 ‎‡a Author's INTRODUCTION: PRACTICE GUIDELINES Helpful Aids or Paradigm Shift?‏
670 ‎‡a Author's Invasive meningococcal disease epidemiology and control measures: a framework for evaluation‏
670 ‎‡a Author's IQWiG methods - a response to two critiques‏
670 ‎‡a Author's ISPOR-SMDM Task Force’s Recommendations for Good Modeling Practices—Reply to Letter to the Editor by Corro Ramos‏
670 ‎‡a Author's Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S‏
670 ‎‡a Author's Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation‏
670 ‎‡a Author's Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation‏
670 ‎‡a Author's Long term cost-of-illness in stroke: an international review‏
670 ‎‡a Author's Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.‏
670 ‎‡a Author's Los modelos de simulación de eventos discretos en la evaluación económica de tecnologías y productos sanitarios‏
670 ‎‡a Author's Lung cancer screening: will the controversy extend to its cost-effectiveness?‏
670 ‎‡a Author's Management patterns and costs of acute ischemic stroke: an international study. For the Stroke Economic Analysis Group.‏
670 ‎‡a Author's Managing meningococcal disease in the United States: Hospital case characteristics and costs by age.‏
670 ‎‡a Author's Medical planning and response for a nuclear detonation: a practical guide‏
670 ‎‡a Author's Medical Research on a Complaint: Orientation and Priorities‏
670 ‎‡a Author's Meta-analysis of longitudinal studies.‏
670 ‎‡a Author's Metabolic effects of regular physical exercise in healthy population‏
670 ‎‡a Author's Methods of economic evaluation for the German statutory healthcare system.‏
670 ‎‡a Author's Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.‏
670 ‎‡a Author's Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.‏
670 ‎‡a Author's Modeling the efficiency of reaching a target intermediate end point: a case study in type 2 diabetes in the United States‏
670 ‎‡a Author's Modeling the implications of changes in vascular calcification in patients on hemodialysis‏
670 ‎‡a Author's Modeling Using Discrete Event Simulation‏
670 ‎‡a Author's Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4‏
670 ‎‡a Author's Modelling the economic and health consequences of cardiac resynchronization therapy in the UK.‏
670 ‎‡a Author's Modelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK.‏
670 ‎‡a Author's New Pertussis Vaccination Strategies beyond Infancy: Recommendations by the Global Pertussis Initiative‏
670 ‎‡a Author's NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?‏
670 ‎‡a Author's No head-to-head trial? simulate the missing arms.‏
670 ‎‡a Author's Optimizing oral anticoagulation in managed care‏
670 ‎‡a Author's Optimizing the design of pragmatic trials: key issues remain‏
670 ‎‡a Author's Oxybutynin Extended Release and Tolterodine Immediate Release‏
670 ‎‡a Author's Pertussis Immunization of Adolescents in the United States‏
670 ‎‡a Author's Pertussis in Adolescents and Adults: Should We Accept the Results?‏
670 ‎‡a Author's Pharmacoeconomic analyses using discrete event simulation‏
670 ‎‡a Author's Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder‏
670 ‎‡a Author's [Pharmacoepidemiology in Mexico]‏
670 ‎‡a Author's Pharmacokinetics in human populations‏
670 ‎‡a Author's Pharmacological management of overactive bladder: a systematic and critical review of published economic evaluations‏
670 ‎‡a Author's Potential strategies to reduce the burden of pertussis‏
670 ‎‡a Author's Predicting Treatment Costs After Acute Ischemic Stroke on the Basis of Patient Characteristics at Presentation and Early Dysfunction‏
670 ‎‡a Author's Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences‏
670 ‎‡a Author's Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting‏
670 ‎‡a Author's Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.‏
670 ‎‡a Author's Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions‏
670 ‎‡a Author's QALYs: are they helpful to decision makers?‏
670 ‎‡a Author's Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care‏
670 ‎‡a Author's Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis‏
670 ‎‡a Author's Re: "Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women" ‏
670 ‎‡a Author's Real-world effectiveness of antihypertensive drugs.‏
670 ‎‡a Author's Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data‏
670 ‎‡a Author's Regarding Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?‏
670 ‎‡a Author's Reply to vascular endothelial growth factor: a novel potential therapeutic target for hypertension‏
670 ‎‡a Author's Resource allocation after a nuclear detonation incident: unaltered standards of ethical decision making.‏
670 ‎‡a Author's Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia‏
670 ‎‡a Author's Scarce resources for nuclear detonation: project overview and challenges‏
670 ‎‡a Author's Secondary prevention fallacy: pitfalls in comparing with primary‏
670 ‎‡a Author's Stages of change for adherence with medication regimens for chronic disease: Development and validation of a measure‏
670 ‎‡a Author's Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature.‏
670 ‎‡a Author's Stroke treatment economic model (STEM): predicting long-term costs from functional status.‏
670 ‎‡a Author's Structural, energetic, and dynamic responses of the native state ensemble of staphylococcal nuclease to cavity-creating mutations.‏
670 ‎‡a Author's Summary: health and economic burden of pertussis‏
670 ‎‡a Author's The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox‏
670 ‎‡a Author's The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: a qualitative review of the literature‏
670 ‎‡a Author's The cost-effectiveness of replacing high-osmolality with low-osmolality contrast media‏
670 ‎‡a Author's The efficiency frontier approach to economic evaluation of health-care interventions.‏
670 ‎‡a Author's The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences‏
670 ‎‡a Author's The global pertussis initiative: Meeting report from the Regional Latin America Meeting, Costa Rica, 5-6 December, 2008.‏
670 ‎‡a Author's The Hanover Consensus: Helpful for German Decision-Makers?‏
670 ‎‡a Author's The impact of compliance with osteoporosis therapy on fracture rates in actual practice‏
670 ‎‡a Author's The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials‏
670 ‎‡a Author's The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database‏
670 ‎‡a Author's The prognostic value of the modified Rankin Scale score for long-term survival after first-ever stroke. Results from the Athens Stroke Registry‏
670 ‎‡a Author's The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.‏
670 ‎‡a Author's The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis‏
670 ‎‡a Author's The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada‏
670 ‎‡a Author's The value of industry-sponsored studies of initial antihypertensive therapies.‏
670 ‎‡a Author's The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.‏
670 ‎‡a Author's To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?‏
670 ‎‡a Author's TP53-inducible Glycolysis and Apoptosis Regulator‏
670 ‎‡a Author's TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer‏
670 ‎‡a Author's Treating acetaminophen overdose: thresholds, costs and uncertainties‏
670 ‎‡a Author's Unaltered ethical standards for individual physicians in the face of drastically reduced resources resulting from an improvised nuclear device event.‏
670 ‎‡a Author's Use of relative effectiveness information in reimbursement and pricing decisions in Europe‏
670 ‎‡a Author's User-managed inventory: an approach to forward-deployment of urgently needed medical countermeasures for mass-casualty and terrorism incidents‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/viaf/239156012425549700006‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/SUDOC|235913235‏
909 ‎‡a (orcid) 0000000154703754‏ ‎‡9 1‏
919 ‎‡a usermanagedinventoryanapproachtoforwarddeploymentofurgentlyneededmedicalcountermeasuresformasscasualtyandterrorismincidents‏ ‎‡A User-managed inventory: an approach to forward-deployment of urgently needed medical countermeasures for mass-casualty and terrorism incidents‏ ‎‡9 1‏
919 ‎‡a interviewwithjjaimecaro‏ ‎‡A An interview with J. Jaime Caro.‏ ‎‡9 1‏
919 ‎‡a budgetaryimpactoftreatingacutebipolarmaniainhospitalizedpatientswithquetiapineaneconomicanalysisofclinicaltrials‏ ‎‡A Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials.‏ ‎‡9 1‏
919 ‎‡a casecontrolstudyofriskfactorsforlargebowelcarcinoma‏ ‎‡A A case-control study of risk factors for large bowel carcinoma.‏ ‎‡9 1‏
919 ‎‡a discreteeventsimulationofsmokingcessationstrategiesbasedonvareniclinepivotaltrialdata‏ ‎‡A A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.‏ ‎‡9 1‏
919 ‎‡a adjustingforpatientcrossoverinclinicaltrialsusingexternaldataacasestudyoflenalidomideforadvancedmultiplemyeloma‏ ‎‡A Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.‏ ‎‡9 1‏
919 ‎‡a allocatingfundsforcardiovasculardiseasepreventioninlightofthencepatp3guidelines‏ ‎‡A Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III guidelines.‏ ‎‡9 1‏
919 ‎‡a alzheimersdiseaseandotherdementiainnursinghomeslevelsofmanagementandcost‏ ‎‡A Alzheimer's disease and other dementia in nursing homes: levels of management and cost‏ ‎‡9 1‏
919 ‎‡a economicevaluationofatenololvscaptoprilinpatientswithtype2diabetes‏ ‎‡A An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes‏ ‎‡9 1‏
919 ‎‡a economicevaluationofatenololvscaptoprilinpatientswithtype2diabetesukpds24‏ ‎‡A An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 24).‏ ‎‡9 1‏
919 ‎‡a economicmodelofstrokeinatrialfibrillationthecostofsuboptimaloralanticoagulation‏ ‎‡A An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation‏ ‎‡9 1‏
919 ‎‡a internationalsurveyofpatientswiththalassemiamajorandtheirviewsaboutsustaininglifelongdesferrioxamineuse‏ ‎‡A An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.‏ ‎‡9 1‏
919 ‎‡a arehypoglycaemiaandotheradverseeffectssimilaramongsulphonylureas‏ ‎‡A Are hypoglycaemia and other adverse effects similar among sulphonylureas?‏ ‎‡9 1‏
919 ‎‡a areprotonpumpinhibitorsthe1choiceforacutetreatmentofgastriculcersametaanalysisofrandomizedclinicaltrials‏ ‎‡A Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials‏ ‎‡9 1‏
919 ‎‡a arethewoscopsclinicalandeconomicfindingsgeneralizabletootherpopulationsacasestudyforbelgiumthewoscopseconomicanalysisgroupwestofscotlandcoronarypreventionstudy‏ ‎‡A Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.‏ ‎‡9 1‏
919 ‎‡a assessingtheeconomicsofvaccinationforneisseriameningitidisinindustrializednationsareviewandrecommendationsforfurtherresearch‏ ‎‡A Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research‏ ‎‡9 1‏
919 ‎‡a assessingthehealthandeconomicimpactofgalantaminetreatmentinpatientswithalzheimersdiseaseinthehealthcaresystemsofdifferentcountries‏ ‎‡A Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries‏ ‎‡9 1‏
919 ‎‡a assessingthevalueofhealthcareinterventionsusingmulticriteriadecisionanalysisareviewoftheliterature‏ ‎‡A Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature‏ ‎‡9 1‏
919 ‎‡a assessmentofcompliancewithosteoporosistreatmentanditsconsequencesinamanagedcarepopulation‏ ‎‡A Assessment of compliance with osteoporosis treatment and its consequences in a managed care population‏ ‎‡9 1‏
919 ‎‡a assessmentofhealtheconomicsinalzheimersdisease‏ ‎‡A Assessment of Health Economics in Alzheimer's Disease‏ ‎‡9 1‏
919 ‎‡a assessmentofhealtheconomicsinalzheimersdiseaseaheadbasedonneedforfulltimecare‏ ‎‡A Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care.‏ ‎‡9 1‏
919 ‎‡a assessmentofhealtheconomicsinalzheimersdiseaseaheadtreatmentwithgalantamineinsweden‏ ‎‡A Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden‏ ‎‡9 1‏
919 ‎‡a assessmentofhealtheconomicsinalzheimersdiseaseaheadtreatmentwithgalantamineintheuk‏ ‎‡A Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.‏ ‎‡9 1‏
919 ‎‡a assessmentoftheassociationbetweenbloodpressurecontrolandhealthcareresourceuse‏ ‎‡A Assessment of the association between blood pressure control and health care resource use‏ ‎‡9 1‏
919 ‎‡a atrialfibrillationandanticoagulationfromrandomisedtrialstopractice‏ ‎‡A Atrial fibrillation and anticoagulation: from randomised trials to practice‏ ‎‡9 1‏
919 ‎‡a autophagyincancerassociatedfibroblastspromotestumorcellsurvivalroleofhypoxiahif1inductionandnfκbactivationinthetumorstromalmicroenvironment‏ ‎‡A Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment‏ ‎‡9 1‏
919 ‎‡a bileafletvalvereplacementcomplicationsandcosts‏ ‎‡A Bileaflet valve replacement: complications and costs‏ ‎‡9 1‏
919 ‎‡a cancostutilityevaluationsinformdecisionmakingaboutinterventionsforlowbackpain‏ ‎‡A Can cost utility evaluations inform decision making about interventions for low back pain?‏ ‎‡9 1‏
919 ‎‡a canadianeconomiccomparisonofextendedreleaseoxybutyninandimmediatereleasetolterodineinthetreatmentofoveractivebladder‏ ‎‡A Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder‏ ‎‡9 1‏
919 ‎‡a careneedsandeconomicconsequencesafteracuteischemicstroketheerlangenstrokeproject‏ ‎‡A Care needs and economic consequences after acute ischemic stroke: the Erlangen Stroke Project‏ ‎‡9 1‏
919 ‎‡a casecontrolstudiesinpharmacoeconomicresearchanoverview‏ ‎‡A Case-control studies in pharmacoeconomic research: an overview.‏ ‎‡9 1‏
919 ‎‡a characterizationofhard2aprocessedhard1geneduplicateencodingahumanproteinnalphaacetyltransferase‏ ‎‡A Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase‏ ‎‡9 1‏
919 ‎‡a clinicalandeconomicburdenofinfusedironchelationtherapyintheunitedstates‏ ‎‡A Clinical and economic burden of infused iron chelation therapy in the United States‏ ‎‡9 1‏
919 ‎‡a communicatingtheparameteruncertaintyintheiqwigefficiencyfrontiertodecisionmakers‏ ‎‡A Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers‏ ‎‡9 1‏
919 ‎‡a complianceandhypertension‏ ‎‡A Compliance and hypertension‏ ‎‡9 1‏
919 ‎‡a compliancewithrefillingprescriptionsforatypicalantipsychoticagentsanditsassociationwiththerisksforhospitalizationsuicideanddeathinpatientswithschizophreniainquebecandsaskatchewanaretrospectivedatabasestudy‏ ‎‡A Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with Schizophrenia in Quebec and Saskatchewan: A retrospective database study‏ ‎‡9 1‏
919 ‎‡a costbenefitanalysisofpreventingsuddencardiacdeathswithanimplantablecardioverterdefibrillatorversusamiodarone‏ ‎‡A Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone‏ ‎‡9 1‏
919 ‎‡a costeffectivenessanalysisofusinghighdosesofatorvastatinforthesecondarystrokepreventioninspain‏ ‎‡A [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain]‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofcardiacresynchronizationtherapy‏ ‎‡A Cost-Effectiveness of Cardiac Resynchronization Therapy‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofclopidogrelplusaspirinversusaspirinaloneforsecondarypreventionofcardiovasculareventsresultsfromthecharismatrial‏ ‎‡A Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofeplerenonecomparedwithplaceboinpatientswithmyocardialinfarctioncomplicatedbyleftventriculardysfunctionandheartfailure‏ ‎‡A Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofeplerenoneinpatientswithheartfailureafteracutemyocardialinfarctionwhoweretakingbothaceinhibitorsandbetablockerssubanalysisoftheephesus‏ ‎‡A Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessoflaparoscopicandminicholecystectomyinaprospectiverandomizedtrial‏ ‎‡A Cost-effectiveness of laparoscopic and mini-cholecystectomy in a prospective randomized trial.‏ ‎‡9 1‏
919 ‎‡a costofmanaginganepisodeofrelapseinmultiplesclerosisintheunitedstates‏ ‎‡A Cost of managing an episode of relapse in multiple sclerosis in the United States‏ ‎‡9 1‏
919 ‎‡a costofmanagingcomplicationsresultingfromtype2diabetesmellitusincanada‏ ‎‡A Cost of managing complications resulting from type 2 diabetes mellitus in Canada‏ ‎‡9 1‏
919 ‎‡a costsandcosteffectivenessofcarotidstentingversusendarterectomyforpatientsatincreasedsurgicalriskresultsfromthesapphiretrial‏ ‎‡A Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPPHIRE trial‏ ‎‡9 1‏
919 ‎‡a costsandeffectivenessofextracorporealgallbladderstoneshockwavelithotripsyversuslaparoscopiccholecystectomyarandomizedclinicaltrialmcgillgallstonetreatmentgroup‏ ‎‡A Costs and effectiveness of extracorporeal gallbladder stone shock wave lithotripsy versus laparoscopic cholecystectomy. A randomized clinical trial. McGill Gallstone Treatment Group‏ ‎‡9 1‏
919 ‎‡a costsandmedicalcareconsequencesassociatedwiththediagnosisofperipheralarterialdisease‏ ‎‡A Costs and Medical Care Consequences Associated with the Diagnosis of Peripheral Arterial Disease‏ ‎‡9 1‏
919 ‎‡a couldchest10rayscreeningforlungcancerbecosteffective‏ ‎‡A Could chest X-ray screening for lung cancer be cost-effective?‏ ‎‡9 1‏
919 ‎‡a decisionanalyticmodelscurrentmethodologicalchallenges‏ ‎‡A Decision-analytic models: current methodological challenges.‏ ‎‡9 1‏
919 ‎‡a describingcognitivedeclineofpatientsatthemildormoderatestagesofalzheimersdiseaseusingthestandardizedmmse‏ ‎‡A Describing cognitive decline of patients at the mild or moderate stages of Alzheimer's disease using the Standardized MMSE.‏ ‎‡9 1‏
919 ‎‡a descriptiveanalysisoftheprocessandqualityoforalanticoagulationmanagementinreallifepracticeinpatientswithchronicnonvalvularatrialfibrillationtheinternationalstudyofanticoagulationmanagement‏ ‎‡A Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management‏ ‎‡9 1‏
919 ‎‡a descriptiveanalysisoftheprocessandqualityoforalanticoagulationmanagementinreallifepracticeinpatientswithchronicnonvalvularatrialfibrillationtheinternationalstudyofanticoagulationmanagementisam‏ ‎‡A Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).‏ ‎‡9 1‏
919 ‎‡a directmedicalcostofmanagingdeepveinthrombosisaccordingtotheoccurrenceofcomplications‏ ‎‡A Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications‏ ‎‡9 1‏
919 ‎‡a directmedicalcostsofcomplicationsresultingfromtype2diabetesintheus‏ ‎‡A Direct medical costs of complications resulting from type 2 diabetes in the U.S.‏ ‎‡9 1‏
919 ‎‡a discreteeventsimulationthepreferredtechniqueforhealtheconomicevaluations‏ ‎‡A Discrete event simulation: the preferred technique for health economic evaluations?‏ ‎‡9 1‏
919 ‎‡a discretelyintegratedconditioneventdicesimulationforpharmacoeconomics‏ ‎‡A Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics‏ ‎‡9 1‏
919 ‎‡a doeselectronicimplementationofquestionnairesusedinasthmaalterresponsescomparedtopaperimplementation‏ ‎‡A Does electronic implementation of questionnaires used in asthma alter responses compared to paper implementation?‏ ‎‡9 1‏
919 ‎‡a economicanalysisofgalantamineacholinesteraseinhibitorinthetreatmentofpatientswithmildtomoderatealzheimersdiseaseinthenetherlands‏ ‎‡A Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands‏ ‎‡9 1‏
919 ‎‡a economicanalysisofinitialhivtreatmentefavirenzversusindinavircontainingtripletherapy‏ ‎‡A Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy‏ ‎‡9 1‏
919 ‎‡a economicandhealthconsequencesofmanagingbradycardiawithdualchambercomparedtosinglechamberventricularpacemakersinitaly‏ ‎‡A Economic and health consequences of managing bradycardia with dual-chamber compared to single-chamber ventricular pacemakers in Italy.‏ ‎‡9 1‏
919 ‎‡a economicassessmentoftroglitazoneasanadjuncttosulfonylureatherapyinthetreatmentoftype2diabetes‏ ‎‡A Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes‏ ‎‡9 1‏
919 ‎‡a economicassessmentsoflowmolecularweightheparininvenousthromboembolism‏ ‎‡A Economic assessments of low molecular weight heparin in venous thromboembolism‏ ‎‡9 1‏
919 ‎‡a economicburdenofpertussisandtheimpactofimmunization‏ ‎‡A Economic burden of pertussis and the impact of immunization‏ ‎‡9 1‏
919 ‎‡a economicevaluationofatorvastatinforpreventionofrecurrentstrokebasedonthesparcltrial‏ ‎‡A Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial‏ ‎‡9 1‏
919 ‎‡a economicevaluationofdoripenemforthetreatmentofnosocomialpneumoniaintheusdiscreteeventsimulation‏ ‎‡A Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation‏ ‎‡9 1‏
919 ‎‡a economicevaluationofgalantamineinthetreatmentofmildtomoderatealzheimersdiseaseintheunitedstates‏ ‎‡A Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States‏ ‎‡9 1‏
919 ‎‡a economicimplicationsofextendedreleasemetoprololsuccinateforheartfailureinthemerithftrialausperspectiveofthemerithftrial‏ ‎‡A Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial‏ ‎‡9 1‏
919 ‎‡a economicimplicationsofgrowthhormoneuseinpatientswithshortbowelsyndrome‏ ‎‡A Economic implications of growth hormone use in patients with short bowel syndrome‏ ‎‡9 1‏
919 ‎‡a economicoutcomesassociatedwithmicrovascularcomplicationsoftype2diabetesmellitusresultsfromausclaimsdataanalysis‏ ‎‡A Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis‏ ‎‡9 1‏
919 ‎‡a estimatesofdirectmedicalcostsformicrovascularandmacrovascularcomplicationsresultingfromtype2diabetesmellitusintheunitedstatesin‏ ‎‡A Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.‏ ‎‡9 1‏
919 ‎‡a estimatesoftheeffectonhepaticironoforaldeferipronecomparedwithsubcutaneousdesferrioxaminefortreatmentofironoverloadinthalassemiamajorasystematicreview‏ ‎‡A Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review‏ ‎‡9 1‏
919 ‎‡a estimatingsurvivalforcosteffectivenessanalysesacasestudyinatherothrombosis‏ ‎‡A Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis‏ ‎‡9 1‏
919 ‎‡a etheneethaneandpropenepropaneseparationviatheolefinandparaffinselectivemetalorganicframeworkadsorbentscpo27andzif8‏ ‎‡A Ethene/ethane and propene/propane separation via the olefin and paraffin selective metal-organic framework adsorbents CPO-27 and ZIF-8.‏ ‎‡9 1‏
919 ‎‡a evaluatingthetruecostofhypertensionmanagementevidencefromactualpractice‏ ‎‡A Evaluating the true cost of hypertension management: evidence from actual practice.‏ ‎‡9 1‏
919 ‎‡a existingtreatmentstrategiesdoesnoncompliancemakeadifference‏ ‎‡A Existing treatment strategies: does noncompliance make a difference?‏ ‎‡9 1‏
919 ‎‡a foundationsofmedicaldiagnosiswhatactuallyaretheparametersinvolvedinbayestheorem‏ ‎‡A Foundations of medical diagnosis: what actually are the parameters involved in Bayes' theorem?‏ ‎‡9 1‏
919 ‎‡a generalizingtheresultsofclinicaltrialstoactualpracticetheexampleofclopidogreltherapyforthepreventionofvascularevents‏ ‎‡A Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events‏ ‎‡9 1‏
919 ‎‡a healingandrelapseratesingastroesophagealrefluxdiseasetreatedwiththenewerprotonpumpinhibitorslansoprazolerabeprazoleandpantoprazolecomparedwithomeprazoleranitidineandplaceboevidencefromrandomizedclinicaltrials‏ ‎‡A Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials‏ ‎‡9 1‏
919 ‎‡a healthandeconomicconsequencesofanoutbreakofpertussisamonghealthcareworkersinahospitalinfrance‏ ‎‡A Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France‏ ‎‡9 1‏
919 ‎‡a healthandeconomicconsequencesofsevelameruseforhyperphosphatemiainpatientsonhemodialysis‏ ‎‡A Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis‏ ‎‡9 1‏
919 ‎‡a healthandeconomiceffectsofaddingnateglinidetometformintoachievedualcontrolofglycosylatedhemoglobinandpostprandialglucoselevelsinamodeloftype2diabetesmellitus‏ ‎‡A Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus‏ ‎‡9 1‏
919 ‎‡a healthandeconomicimpactofcombiningmetforminwithnateglinidetoachieveglycemiccontrolcomparisonofthelifetimecostsofcomplicationsintheuk‏ ‎‡A Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K‏ ‎‡9 1‏
919 ‎‡a hif1alphafunctionsasatumorpromoterincancerassociatedfibroblastsandasatumorsuppressorinbreastcancercellsautophagydrivescompartmentspecificoncogenesis‏ ‎‡A HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis‏ ‎‡9 1‏
919 ‎‡a hospitalizationforpertussisprofilesandcasecostsbyage‏ ‎‡A Hospitalization for pertussis: profiles and case costs by age.‏ ‎‡9 1‏
919 ‎‡a howcosteffectivearedrugsanddevicesusedincardiology‏ ‎‡A How cost-effective are drugs and devices used in cardiology?‏ ‎‡9 1‏
919 ‎‡a howrelevantiscosteffectivenessanyway‏ ‎‡A How relevant is cost-effectiveness anyway?‏ ‎‡9 1‏
919 ‎‡a ignoringstudydesignheterogeneityinmetaanalyses‏ ‎‡A Ignoring Study Design Heterogeneity in Meta-analyses‏ ‎‡9 1‏
919 ‎‡a impactofphysicalfunctioningofhealthstatusonhospitalizationsphysicianvisitsandcostsindiabeticpatients‏ ‎‡A Impact of Physical Functioning of Health Status on Hospitalizations, Physician Visits, and Costs in Diabetic Patients‏ ‎‡9 1‏
919 ‎‡a impactofthalassemiamajoronpatientsandtheirfamilies‏ ‎‡A Impact of thalassemia major on patients and their families‏ ‎‡9 1‏
919 ‎‡a improvingtransparencyindecisionmodelscurrentissuesandpotentialsolutions‏ ‎‡A Improving Transparency in Decision Models: Current Issues and Potential Solutions‏ ‎‡9 1‏
919 ‎‡a interactionbetweenhif1alphaoddandhard1doesnotinduceacetylationanddestabilizationofhif1alpha‏ ‎‡A Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha‏ ‎‡9 1‏
919 ‎‡a internationaleconomicanalysisofprimarypreventionofcardiovasculardiseasewithpravastatininwoscopswestofscotlandcoronarypreventionstudy‏ ‎‡A International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.‏ ‎‡9 1‏
919 ‎‡a introductionpracticeguidelineshelpfulaidsorparadigmshift‏ ‎‡A INTRODUCTION: PRACTICE GUIDELINES Helpful Aids or Paradigm Shift?‏ ‎‡9 1‏
919 ‎‡a invasivemeningococcaldiseaseepidemiologyandcontrolmeasuresaframeworkforevaluation‏ ‎‡A Invasive meningococcal disease epidemiology and control measures: a framework for evaluation‏ ‎‡9 1‏
919 ‎‡a iqwigmethodsaresponseto2critiques‏ ‎‡A IQWiG methods - a response to two critiques‏ ‎‡9 1‏
919 ‎‡a isporsmdmtaskforcesrecommendationsforgoodmodelingpracticesreplytolettertotheeditorbycorroramos‏ ‎‡A ISPOR-SMDM Task Force’s Recommendations for Good Modeling Practices—Reply to Letter to the Editor by Corro Ramos‏ ‎‡9 1‏
919 ‎‡a lifetimecostsofcomplicationsresultingfromtype2diabetesintheus‏ ‎‡A Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S‏ ‎‡9 1‏
919 ‎‡a longtermcosteffectivenessofclopidogrelgivenforupto1yearinpatientswithacutecoronarysyndromeswithoutstsegmentelevation‏ ‎‡A Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation‏ ‎‡9 1‏
919 ‎‡a longtermcosteffectivenessofearlyandsustainedclopidogreltherapyforupto1yearinpatientsundergoingpercutaneouscoronaryinterventionafterpresentingwithacutecoronarysyndromeswithoutstsegmentelevation‏ ‎‡A Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation‏ ‎‡9 1‏
919 ‎‡a longtermcostofillnessinstrokeaninternationalreview‏ ‎‡A Long term cost-of-illness in stroke: an international review‏ ‎‡9 1‏
919 ‎‡a lopinavirritonavirversusdarunavirplusritonavirforhivinfectionacosteffectivenessanalysisfortheunitedstates‏ ‎‡A Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.‏ ‎‡9 1‏
919 ‎‡a modelosdesimulaciondeeventosdiscretosenlaevaluacioneconomicadetecnologiasyproductossanitarios‏ ‎‡A Los modelos de simulación de eventos discretos en la evaluación económica de tecnologías y productos sanitarios‏ ‎‡9 1‏
919 ‎‡a lungcancerscreeningwillthecontroversyextendtoitscosteffectiveness‏ ‎‡A Lung cancer screening: will the controversy extend to its cost-effectiveness?‏ ‎‡9 1‏
919 ‎‡a managementpatternsandcostsofacuteischemicstrokeaninternationalstudyforthestrokeeconomicanalysisgroup‏ ‎‡A Management patterns and costs of acute ischemic stroke: an international study. For the Stroke Economic Analysis Group.‏ ‎‡9 1‏
919 ‎‡a managingmeningococcaldiseaseintheunitedstateshospitalcasecharacteristicsandcostsbyage‏ ‎‡A Managing meningococcal disease in the United States: Hospital case characteristics and costs by age.‏ ‎‡9 1‏
919 ‎‡a medicalplanningandresponseforanucleardetonationapracticalguide‏ ‎‡A Medical planning and response for a nuclear detonation: a practical guide‏ ‎‡9 1‏
919 ‎‡a medicalresearchonacomplaintorientationandpriorities‏ ‎‡A Medical Research on a Complaint: Orientation and Priorities‏ ‎‡9 1‏
919 ‎‡a metaanalysisoflongitudinalstudies‏ ‎‡A Meta-analysis of longitudinal studies.‏ ‎‡9 1‏
919 ‎‡a metaboliceffectsofregularphysicalexerciseinhealthypopulation‏ ‎‡A Metabolic effects of regular physical exercise in healthy population‏ ‎‡9 1‏
919 ‎‡a methodsofeconomicevaluationforthegermanstatutoryhealthcaresystem‏ ‎‡A Methods of economic evaluation for the German statutory healthcare system.‏ ‎‡9 1‏
919 ‎‡a modeltransparencyandvalidationareportoftheisporsmdmmodelinggoodresearchpracticestaskforce7‏ ‎‡A Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.‏ ‎‡9 1‏
919 ‎‡a modelinggoodresearchpracticesoverviewareportoftheisporsmdmmodelinggoodresearchpracticestaskforce1‏ ‎‡A Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.‏ ‎‡9 1‏
919 ‎‡a modelingtheefficiencyofreachingatargetintermediateendpointacasestudyintype2diabetesintheunitedstates‏ ‎‡A Modeling the efficiency of reaching a target intermediate end point: a case study in type 2 diabetes in the United States‏ ‎‡9 1‏
919 ‎‡a modelingtheimplicationsofchangesinvascularcalcificationinpatientsonhemodialysis‏ ‎‡A Modeling the implications of changes in vascular calcification in patients on hemodialysis‏ ‎‡9 1‏
919 ‎‡a modelingusingdiscreteeventsimulation‏ ‎‡A Modeling Using Discrete Event Simulation‏ ‎‡9 1‏
919 ‎‡a modelingusingdiscreteeventsimulationareportoftheisporsmdmmodelinggoodresearchpracticestaskforce4‏ ‎‡A Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4‏ ‎‡9 1‏
919 ‎‡a modellingtheeconomicandhealthconsequencesofcardiacresynchronizationtherapyintheuk‏ ‎‡A Modelling the economic and health consequences of cardiac resynchronization therapy in the UK.‏ ‎‡9 1‏
919 ‎‡a modellingthehealthbenefitsandeconomicimplicationsofimplantingdualchambervssinglechamberventricularpacemakersintheuk‏ ‎‡A Modelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK.‏ ‎‡9 1‏
919 ‎‡a newpertussisvaccinationstrategiesbeyondinfancyrecommendationsbytheglobalpertussisinitiative‏ ‎‡A New Pertussis Vaccination Strategies beyond Infancy: Recommendations by the Global Pertussis Initiative‏ ‎‡9 1‏
919 ‎‡a nicecosteffectivenessappraisalofcholinesteraseinhibitorswastherightquestionposedwerethebesttoolsused‏ ‎‡A NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?‏ ‎‡9 1‏
919 ‎‡a noheadtoheadtrialsimulatethemissingarms‏ ‎‡A No head-to-head trial? simulate the missing arms.‏ ‎‡9 1‏
919 ‎‡a optimizingoralanticoagulationinmanagedcare‏ ‎‡A Optimizing oral anticoagulation in managed care‏ ‎‡9 1‏
919 ‎‡a optimizingthedesignofpragmatictrialskeyissuesremain‏ ‎‡A Optimizing the design of pragmatic trials: key issues remain‏ ‎‡9 1‏
919 ‎‡a oxybutyninextendedreleaseandtolterodineimmediaterelease‏ ‎‡A Oxybutynin Extended Release and Tolterodine Immediate Release‏ ‎‡9 1‏
919 ‎‡a pertussisimmunizationofadolescentsintheunitedstates‏ ‎‡A Pertussis Immunization of Adolescents in the United States‏ ‎‡9 1‏
919 ‎‡a pertussisinadolescentsandadultsshouldweaccepttheresults‏ ‎‡A Pertussis in Adolescents and Adults: Should We Accept the Results?‏ ‎‡9 1‏
919 ‎‡a pharmacoeconomicanalysesusingdiscreteeventsimulation‏ ‎‡A Pharmacoeconomic analyses using discrete event simulation‏ ‎‡9 1‏
919 ‎‡a pharmacoeconomicsofquetiapineforthemanagementofacutemaniainbipolar1disorder‏ ‎‡A Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder‏ ‎‡9 1‏
919 ‎‡a pharmacoepidemiologyinmexico‏ ‎‡A [Pharmacoepidemiology in Mexico]‏ ‎‡9 1‏
919 ‎‡a pharmacokineticsinhumanpopulations‏ ‎‡A Pharmacokinetics in human populations‏ ‎‡9 1‏
919 ‎‡a pharmacologicalmanagementofoveractivebladderasystematicandcriticalreviewofpublishedeconomicevaluations‏ ‎‡A Pharmacological management of overactive bladder: a systematic and critical review of published economic evaluations‏ ‎‡9 1‏
919 ‎‡a potentialstrategiestoreducetheburdenofpertussis‏ ‎‡A Potential strategies to reduce the burden of pertussis‏ ‎‡9 1‏
919 ‎‡a predictingtreatmentcostsafteracuteischemicstrokeonthebasisofpatientcharacteristicsatpresentationandearlydysfunction‏ ‎‡A Predicting Treatment Costs After Acute Ischemic Stroke on the Basis of Patient Characteristics at Presentation and Early Dysfunction‏ ‎‡9 1‏
919 ‎‡a preventionandmanagementofhyperphosphatemiawithsevelamerincanadahealthandeconomicconsequences‏ ‎‡A Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences‏ ‎‡9 1‏
919 ‎‡a preventionofpertussisrecommendationsderivedfromthe2globalpertussisinitiativeroundtablemeeting‏ ‎‡A Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting‏ ‎‡9 1‏
919 ‎‡a principlesofgoodpracticeforbudgetimpactanalysisreportoftheisportaskforceongoodresearchpracticesbudgetimpactanalysis‏ ‎‡A Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.‏ ‎‡9 1‏
919 ‎‡a principlesofnonexperimentalassessmentofexcessriskwithspecialreferencetoadversedrugreactions‏ ‎‡A Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions‏ ‎‡9 1‏
919 ‎‡a qalysaretheyhelpfultodecisionmakers‏ ‎‡A QALYs: are they helpful to decision makers?‏ ‎‡9 1‏
919 ‎‡a qualityofclinicaldocumentationandanticoagulationcontrolinpatientswithchronicnonvalvularatrialfibrillationinroutinemedicalcare‏ ‎‡A Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care‏ ‎‡9 1‏
919 ‎‡a rationalchoiceofcholinesteraseinhibitorforthetreatmentofalzheimersdiseaseincanadaacomparativeeconomicanalysis‏ ‎‡A Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis‏ ‎‡9 1‏
919 ‎‡a recharacteristicsrelatingtoovariancancerriskcollaborativeanalysisof12uscasecontrolstudies2invasiveepithelialovariancancersinwhitewomen‏ ‎‡A Re: "Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women" ‏ ‎‡9 1‏
919 ‎‡a realworldeffectivenessofantihypertensivedrugs‏ ‎‡A Real-world effectiveness of antihypertensive drugs.‏ ‎‡9 1‏
919 ‎‡a recommendationsforevaluatingcomplianceandpersistencewithhypertensiontherapyusingretrospectivedata‏ ‎‡A Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data‏ ‎‡9 1‏
919 ‎‡a regardingprobabilisticanalysisandcomputationallyexpensivemodelsnecessaryandrequired‏ ‎‡A Regarding Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?‏ ‎‡9 1‏
919 ‎‡a replytovascularendothelialgrowthfactoranovelpotentialtherapeutictargetforhypertension‏ ‎‡A Reply to vascular endothelial growth factor: a novel potential therapeutic target for hypertension‏ ‎‡9 1‏
919 ‎‡a resourceallocationafteranucleardetonationincidentunalteredstandardsofethicaldecisionmaking‏ ‎‡A Resource allocation after a nuclear detonation incident: unaltered standards of ethical decision making.‏ ‎‡9 1‏
919 ‎‡a riskofdiscontinuationofrisperidoneafterexposuretopotentiallyinteractingdrugsanestedcasecontrolstudyinpatientswithschizophrenia‏ ‎‡A Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia‏ ‎‡9 1‏
919 ‎‡a scarceresourcesfornucleardetonationprojectoverviewandchallenges‏ ‎‡A Scarce resources for nuclear detonation: project overview and challenges‏ ‎‡9 1‏
919 ‎‡a secondarypreventionfallacypitfallsincomparingwithprimary‏ ‎‡A Secondary prevention fallacy: pitfalls in comparing with primary‏ ‎‡9 1‏
919 ‎‡a stagesofchangeforadherencewithmedicationregimensforchronicdiseasedevelopmentandvalidationofameasure‏ ‎‡A Stages of change for adherence with medication regimens for chronic disease: Development and validation of a measure‏ ‎‡9 1‏
919 ‎‡a strategiesforthemanagementofhypercholesterolaemiaasystematicreviewofthecosteffectivenessliterature‏ ‎‡A Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature.‏ ‎‡9 1‏
919 ‎‡a stroketreatmenteconomicmodelstempredictinglongtermcostsfromfunctionalstatus‏ ‎‡A Stroke treatment economic model (STEM): predicting long-term costs from functional status.‏ ‎‡9 1‏
919 ‎‡a structuralenergeticanddynamicresponsesofthenativestateensembleofstaphylococcalnucleasetocavitycreatingmutations‏ ‎‡A Structural, energetic, and dynamic responses of the native state ensemble of staphylococcal nuclease to cavity-creating mutations.‏ ‎‡9 1‏
919 ‎‡a summaryhealthandeconomicburdenofpertussis‏ ‎‡A Summary: health and economic burden of pertussis‏ ‎‡9 1‏
919 ‎‡a autophagictumorstromamodelofcancerorbatteryoperatedtumorgrowthasimplesolutiontotheautophagyparadox‏ ‎‡A The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox‏ ‎‡9 1‏
919 ‎‡a barthelindexandmodifiedrankinscaleasprognostictoolsforlongtermoutcomesafterstrokeaqualitativereviewoftheliterature‏ ‎‡A The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: a qualitative review of the literature‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofreplacinghighosmolalitywithlowosmolalitycontrastmedia‏ ‎‡A The cost-effectiveness of replacing high-osmolality with low-osmolality contrast media‏ ‎‡9 1‏
919 ‎‡a efficiencyfrontierapproachtoeconomicevaluationofhealthcareinterventions‏ ‎‡A The efficiency frontier approach to economic evaluation of health-care interventions.‏ ‎‡9 1‏
919 ‎‡a emerginginfectiouschallengeofclostridiumdifficileassociateddiseaseinmassachusettshospitalsclinicalandeconomicconsequences‏ ‎‡A The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences‏ ‎‡9 1‏
919 ‎‡a globalpertussisinitiativemeetingreportfromtheregionallatinamericameetingcostarica56december‏ ‎‡A The global pertussis initiative: Meeting report from the Regional Latin America Meeting, Costa Rica, 5-6 December, 2008.‏ ‎‡9 1‏
919 ‎‡a hanoverconsensushelpfulforgermandecisionmakers‏ ‎‡A The Hanover Consensus: Helpful for German Decision-Makers?‏ ‎‡9 1‏
919 ‎‡a impactofcompliancewithosteoporosistherapyonfractureratesinactualpractice‏ ‎‡A The impact of compliance with osteoporosis therapy on fracture rates in actual practice‏ ‎‡9 1‏
919 ‎‡a importanceofpatientreportedoutcomesacallfortheircomprehensiveintegrationincardiovascularclinicaltrials‏ ‎‡A The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials‏ ‎‡9 1‏
919 ‎‡a morbidityandmortalityfollowingadiagnosisofperipheralarterialdiseaselongtermfollowupofalargedatabase‏ ‎‡A The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database‏ ‎‡9 1‏
919 ‎‡a prognosticvalueofthemodifiedrankinscalescoreforlongtermsurvivalafter1everstrokeresultsfromtheathensstrokeregistry‏ ‎‡A The prognostic value of the modified Rankin Scale score for long-term survival after first-ever stroke. Results from the Athens Stroke Registry‏ ‎‡9 1‏
919 ‎‡a riskofdiabetesduringolanzapineusecomparedwithrisperidoneusearetrospectivedatabaseanalysis‏ ‎‡A The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.‏ ‎‡9 1‏
919 ‎‡a risksofdeathandofseverenonfatalreactionswithhighvslowosmolalitycontrastmediaametaanalysis‏ ‎‡A The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis‏ ‎‡9 1‏
919 ‎‡a timecourseofsubsequenthospitalizationsandassociatedcostsinsurvivorsofanischemicstrokeincanada‏ ‎‡A The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada‏ ‎‡9 1‏
919 ‎‡a valueofindustrysponsoredstudiesofinitialantihypertensivetherapies‏ ‎‡A The value of industry-sponsored studies of initial antihypertensive therapies.‏ ‎‡9 1‏
919 ‎‡a westofscotlandcoronarypreventionstudyeconomicbenefitanalysisofprimarypreventionwithpravastatin‏ ‎‡A The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.‏ ‎‡9 1‏
919 ‎‡a towhatdegreedoescognitiveimpairmentinalzheimersdiseasepredictdependenceofpatientsoncaregivers‏ ‎‡A To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?‏ ‎‡9 1‏
919 ‎‡a tp53inducibleglycolysisandapoptosisregulator‏ ‎‡A TP53-inducible Glycolysis and Apoptosis Regulator‏ ‎‡9 1‏
919 ‎‡a tp53inducibleglycolysisandapoptosisregulatortigarmetabolicallyreprogramscarcinomaandstromalcellsinbreastcancer‏ ‎‡A TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer‏ ‎‡9 1‏
919 ‎‡a treatingacetaminophenoverdosethresholdscostsanduncertainties‏ ‎‡A Treating acetaminophen overdose: thresholds, costs and uncertainties‏ ‎‡9 1‏
919 ‎‡a unalteredethicalstandardsforindividualphysiciansinthefaceofdrasticallyreducedresourcesresultingfromanimprovisednucleardeviceevent‏ ‎‡A Unaltered ethical standards for individual physicians in the face of drastically reduced resources resulting from an improvised nuclear device event.‏ ‎‡9 1‏
919 ‎‡a useofrelativeeffectivenessinformationinreimbursementandpricingdecisionsineurope‏ ‎‡A Use of relative effectiveness information in reimbursement and pricing decisions in Europe‏ ‎‡9 1‏
943 ‎‡a 200x‏ ‎‡A 2000‏ ‎‡9 2‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 BNE|XX917471‏
996 ‎‡2 PLWABN|9810553524405606‏
996 ‎‡2 ISNI|0000000076104173‏
996 ‎‡2 NII|DA1511237X‏
996 ‎‡2 PLWABN|9810807643905606‏
996 ‎‡2 DNB|171203755‏
996 ‎‡2 ISNI|000000038568225X‏
996 ‎‡2 PLWABN|9810683027805606‏
996 ‎‡2 LC|n 79141754‏
996 ‎‡2 B2Q|0000297212‏
996 ‎‡2 LC|no2004018961‏
996 ‎‡2 ISNI|0000000399728685‏
996 ‎‡2 ISNI|000000004724322X‏
996 ‎‡2 ISNI|0000000043811648‏
996 ‎‡2 ISNI|0000000360042045‏
996 ‎‡2 NDL|001111605‏
996 ‎‡2 SZ|1208801171‏
996 ‎‡2 LC|no2015162273‏
996 ‎‡2 LC|nb2016005111‏
996 ‎‡2 BAV|495_174298‏
996 ‎‡2 CAOONL|ncf10311753‏
996 ‎‡2 ISNI|0000000452878691‏
996 ‎‡2 NUKAT|n 2019155672‏
996 ‎‡2 J9U|987007345486105171‏
996 ‎‡2 ISNI|000000039328768X‏
996 ‎‡2 DNB|1208801171‏
996 ‎‡2 SUDOC|156864614‏
996 ‎‡2 J9U|987007355380605171‏
996 ‎‡2 LC|no2007022417‏
996 ‎‡2 BIBSYS|9063316‏
996 ‎‡2 CAOONL|ncf10812163‏
996 ‎‡2 DNB|126269505‏
996 ‎‡2 DNB|1194573975‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998 ‎‡a Jaime, Caro,‏ ‎‡2 SUDOC|235913235‏ ‎‡3 suggested‏